Esperion Therapeutics (ESPR) Research & Development (2018 - 2025)
Historic Research & Development for Esperion Therapeutics (ESPR) over the last 8 years, with Q3 2025 value amounting to $14.1 million.
- Esperion Therapeutics' Research & Development rose 3591.42% to $14.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $44.9 million, marking a year-over-year decrease of 1528.22%. This contributed to the annual value of $46.2 million for FY2024, which is 4630.17% down from last year.
- Per Esperion Therapeutics' latest filing, its Research & Development stood at $14.1 million for Q3 2025, which was up 3591.42% from $7.2 million recorded in Q2 2025.
- In the past 5 years, Esperion Therapeutics' Research & Development ranged from a high of $33.0 million in Q4 2022 and a low of $7.2 million during Q2 2025
- Moreover, its 5-year median value for Research & Development was $22.1 million (2023), whereas its average is $20.6 million.
- In the last 5 years, Esperion Therapeutics' Research & Development plummeted by 5728.94% in 2024 and then surged by 3591.42% in 2025.
- Esperion Therapeutics' Research & Development (Quarter) stood at $27.6 million in 2021, then grew by 19.62% to $33.0 million in 2022, then crashed by 46.29% to $17.7 million in 2023, then crashed by 38.13% to $11.0 million in 2024, then grew by 28.73% to $14.1 million in 2025.
- Its Research & Development stands at $14.1 million for Q3 2025, versus $7.2 million for Q2 2025 and $12.6 million for Q1 2025.